Trial Profile
A phase IIIb study on the changes in ocular signs, symptoms and conjunctival inflammatory markers in patients with ocular hypertension or open-angle glaucoma switched from preserved latanoprost 0.005% eye drops to preservative free tafluprost 0.0015% eye drops.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2014
Price :
$35
*
At a glance
- Drugs Tafluprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Santen Oy
- 03 Nov 2014 New trial record